Infectious Disease View
Our researchers cover key aspects of the malaria drug discovery pipeline including biological testing and target identification (Creek), medicinal chemistry (Baell, Scammells, Norton, Devine, Sanchis), drug metabolism and pharmacokinetics (Charman), formulation (Boyd, Clulow, Charman) and pharmacokinetic/pharmacodynamic evaluation (Kirkpatrick).
Application of omics techniques to understand antimalarial drug resistance mechanisms and discover novel diagnostic tools (Creek).
Medicinal chemistry (Baell), biological evaluation (Creek) and drug metabolism/pharmacokinetics (Charman) of new drugs for neglected parasitic diseases including Schistosomiasis, Leishmaniasis, Chagas Diseases and Human African Trypanosomiasis.
Discovery of new antibiotics with medicinal chemistry and biochemical approaches (Scanlon, Capuano), development of long-acting formulations (Boyd, Voelcker) and antibiotic materials (Whittaker, Voelcker).
Development of biosensors for specific pathogens (Voelcker) and pharmacokinetic/pharmacodynamics-based optimisation of antibiotic treatment regimens for multi-drug resistant infections (Landersdorfer, Nation).
Structure-based discovery of new antiviral compounds (Chalmers).
New mRNA-based vaccine strategies to prevent viral infections including COVID-19 (Pouton).
Maternal, Child and Reproductive health View
Development of a novel inhaled oxytocin dry powder inhaler for prevention and treatment of PPH in resource poor settings (McIntosh, Lambert).
Post marketing surveillance and assessment of the quality of essential medicines for maternal and newborn health (McIntosh, Lambert).
Development of an optimised long acting paediatric benzylpenicillin (penicillin G) injection for rheumatic heart disease (Boyd).
Development of milk-based formulations of poorly water soluble drugs for paediatric populations (Boyd).
Pharmacological characterisation of non-hormonal male contraceptive candidates (Ventura).
Pharmacological evaluation (Exintaris) and synthesis of new drug candidates (Whittaker) for benign prostatic hyperplasia.
Capacity Building for Pharmacy View
Mapping the structure and content of competency frameworks for pharmacists and facilitating development of national competency frameworks (Jackson)
Development of harmonised policies and frameworks for pharmacy practice in the Western Pacific region (Jackson).
Other Therapeutic Program Areas